Get access

Modest efficacy of voriconazole against murine infections by Sporothrix schenckii and lack of efficacy against Sporothrix brasiliensis

Authors

  • Fabiola Fernández-Silva,

    1. Unitat d′Anatomia Patológica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain
    Search for more papers by this author
  • Javier Capilla,

    1. Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain
    Search for more papers by this author
  • Emilio Mayayo,

    1. Unitat d′Anatomia Patológica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain
    Search for more papers by this author
  • Josep Guarro

    Corresponding author
    1. Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain
    • Correspondence: J. Guarro, Unitat de Microbiologia, Departament de Ciències Mèdiques Bàsiques, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Carrer Sant Llorenç 21, Reus, Spain.

      Tel.: 34 977 759359. Fax: 34 977 759322.

      E-mail: josep.guarro@urv.cat

    Search for more papers by this author

Summary

The efficacy of voriconazole (VRC) was evaluated against two strains of each of the two most common species causing sporotrichosis, Sporothrix schenckii sensu stricto and Sporothrix brasiliensis, using a murine model of disseminated infection. Voriconazole was administered at doses of 20 or 40 mg kg−1 per day by gavage. The drug showed some efficacy, especially at 40 mg kg−1 per day, in prolonging the survival and reducing fungal load in spleen and liver in mice infected with S. schenckii, whereas in animals infected with S. brasiliensis the drug did not work.

Ancillary